{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:34:21Z","timestamp":1789644861949,"version":"4.0.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urology Case Reports"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.eucr.2026.103368","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T16:46:38Z","timestamp":1770655598000},"page":"103368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the urological health"],"prefix":"10.1016","volume":"65","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6861-1911","authenticated-orcid":false,"given":"Arisha","family":"Tariq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Garza Gangemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Herrera Caceres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3-4","key":"10.1016\/j.eucr.2026.103368_bib1","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud : Reg Dev Stud"},{"key":"10.1016\/j.eucr.2026.103368_bib2","series-title":"GLP-1 Injectable Use Among Adults with Diagnosed Diabetes, United States, 2024 (NCHS Data Brief No. 537)","year":"2025"},{"issue":"3","key":"10.1016\/j.eucr.2026.103368_bib3","article-title":"Spending on glucagon-like peptide-1 receptor agonists among U.S. adults","volume":"8","author":"Tsipas","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.eucr.2026.103368_bib4","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvad016","article-title":"Adverse events related to tirzepatide","volume":"7","author":"Mishra","year":"2023","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.eucr.2026.103368_bib5","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.2147\/DMSO.S537229","article-title":"Comparative safety of GLP-1\/GIP Co-Agonists versus GLP-1 receptor agonists for weight loss in patients with obesity or overweight: a systematic review","volume":"18","author":"Xie","year":"2025","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"3","key":"10.1016\/j.eucr.2026.103368_bib6","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3390\/ph18030399","article-title":"Semaglutide as a GLP-1 agonist: efficacy and adverse effects","volume":"18","author":"Salvador","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.eucr.2026.103368_bib7","doi-asserted-by":"crossref","DOI":"10.4239\/wjd.v16.i2.101282","article-title":"Renal effects and safety of tirzepatide in subjects with and without diabetes: a systematic review and meta-analysis","volume":"16","author":"Kamrul-Hasan","year":"2025","journal-title":"World J Diabetes"},{"issue":"6","key":"10.1016\/j.eucr.2026.103368_bib8","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2337\/dc24-2169","article-title":"Risk of urogenital infections in people with type 2 diabetes initiating GLP-1 receptor agonists versus SGLT2 inhibitors: a nationwide cohort study","volume":"48","author":"Ljungberg","year":"2025","journal-title":"Diabetes Care"},{"issue":"11","key":"10.1016\/j.eucr.2026.103368_bib9","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3390\/toxins17110542","article-title":"Concurrent GLP-1 receptor agonist use is associated with reduced urinary adverse events following onabotulinumtoxinA treatment in non-diabetic adults with overactive bladder","volume":"17","author":"Hammad","year":"2025","journal-title":"Toxins"},{"issue":"2","key":"10.1016\/j.eucr.2026.103368_bib11","first-page":"87","article-title":"Effects of GLP-1 receptor agonists on overactive bladder symptom patterns","volume":"12","author":"Sandler","year":"2025","journal-title":"Urol Pract"},{"key":"10.1016\/j.eucr.2026.103368_bib12","article-title":"Effect of treatment with GLP-1 receptor agonists on the urinary peptidome of patients with type 2 diabetes mellitus","author":"Lohia","year":"2023","journal-title":"medRxiv"},{"issue":"5 Suppl","key":"10.1016\/j.eucr.2026.103368_bib13","first-page":"S61","article-title":"Mechanisms in prostatitis\/chronic pelvic pain syndrome","volume":"179","author":"Pontari","year":"2008","journal-title":"J Urol"},{"issue":"8","key":"10.1016\/j.eucr.2026.103368_bib14","doi-asserted-by":"crossref","first-page":"e2710","DOI":"10.1210\/clinem\/dgaa327","article-title":"GIP as a therapeutic target in diabetes and obesity: insight from incretin Co-agonists","volume":"105","author":"Holst","year":"2020","journal-title":"J Clin Endocrinol Metabol"},{"issue":"4","key":"10.1016\/j.eucr.2026.103368_bib15","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"Suppl 1","key":"10.1016\/j.eucr.2026.103368_bib16","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1097\/j.pain.0000000000001551","article-title":"Neuropathic itch","volume":"160","author":"Steinhoff","year":"2019","journal-title":"Pain"},{"key":"10.1016\/j.eucr.2026.103368_bib17","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1463657","article-title":"Analysis of tirzepatide in the US FDA adverse event reporting system (FAERS): a focus on overall patient population and sex-specific subgroups","volume":"15","author":"Ou","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.eucr.2026.103368_bib18","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1502047","article-title":"A real-world data analysis of tirzepatide in the FDA adverse event reporting system (FAERS) database","volume":"15","author":"Liu","year":"2024","journal-title":"Front Pharmacol"}],"container-title":["Urology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442026000318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2214442026000318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T15:41:58Z","timestamp":1781278918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214442026000318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":17,"alternative-id":["S2214442026000318"],"URL":"https:\/\/doi.org\/10.1016\/j.eucr.2026.103368","relation":{},"ISSN":["2214-4420"],"issn-type":[{"value":"2214-4420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the urological health","name":"articletitle","label":"Article Title"},{"value":"Urology Case Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eucr.2026.103368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"103368"}}